Trial Profile
A Randomised Open-Label Phase II Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric Adenocarcinoma (including Adenocarcinoma of the Lower Third of the Oesophagus or the Gastro-Oesophageal Junction) with FGFR2 Polysomy or Gene Amplification (Shine study) - SHINE
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs ABSK 091 (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms SHINE
- Sponsors AstraZeneca
- 30 Jun 2020 Status changed from discontinued to completed.
- 21 Jun 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 02 Jun 2015 Results (n=71) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.